• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Galenica lays foundation for two listed, independent companies

Galenica lays foundation for two listed, independent companies

August 13, 2014
CenterWatch Staff

The Galenica Group, a Switzerland-based healthcare group that develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks, plans to separate into two independent companies.

Current company changes to prepare for the separation include changes at the executive level. The group will be headed by two CEOs: one CEO for Vifor Pharma (the former Pharma division) and one CEO for Galenica Santé (the former Santé division). Both CEOs will report directly to the executive chairman. The role of CEO, Galenica Group is being abolished.

The new management structure will enable the different Pharma and Santé business models to develop in a more focused way based on their individual growth dynamics. With this move, Galenica Group prepares the Vifor Pharma and Galenica Santé units to become independent companies in the future.

The board of Galenica Group has appointed Søren Tulstrup CEO of the Vifor Pharma division and Jörg Kneubühler CEO of the Galenica Santé division. Jörg Kneubühler also will continue as chief financial officer of the Galenica Group. The new structure is effective immediately.

David Ebsworth, who has been CEO of Vifor Pharma since 2009 and was appointed CEO of Galenica Group in 2011, has decided to step down from his operational duties and retire, effective Aug. 31, 2015. He will continue to support the Galenica Group in a special projects role.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing